PD-L1/B7-H1/CD274 Immune Checkpoint Inhibitors

PD-L1 / B7-H1 / CD274 immune checkpoint inhibitors are drugs, most of which are antibodies, targeting PD-L1 / B7-H1 / CD274 immune checkpoint molecule. These PD-L1 / B7-H1 / CD274 immune checkpoint inhibitors are applied to treat cancer. Many PD1/PDCD1/CD279 immune checkpoint inhibitors have been developed or under research. These PD-L1 / B7-H1 / CD274 immune checkpoint inhibitors include BMS-936559, MEDI4736, MPDL3280A, Avelumab and so on. They are tested in multiple cancers: Melanoma, Non-small cell lung cancer, Small cell lung cancer……

PD-L1/B7-H1/CD274 Immune Checkpoint Inhibitors: Developments

Disease PD-L1/B7-H1/CD274 immune checkpoint inhibitors research development
Melanoma BMS-936559 ——a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug, BMS-936559 is being tested in a dose escalation phase I/II study in pretreated patients with a variety of malignancies (Brahmer JR et al. 2012).
MEDI4736 —— a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug, is being tested in a phase I/II trial for melanoma.(Julie R et al. 2014).
MPDL3280A—— a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug, is being tested in numerous cancers in a phase I trial in melanoma (Omid Hamid et al. 2013)
Non-small cell lung cancer

MPDL3280A —— a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug for NSCLC, which is also a humanized monoclonal antibody with a modified Fc receptor designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDCC).It has been evaluated in a dose-ranging phase 1 study that included an expansion cohort of previously treated patients with advanced NSCLC (David R et al 2013).
BMS-936559 ——another PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug for NSCLC, and has been tested in Phase I (Brahmer et al. 2012).
MEDI4736 —— a human IgG1k monoclonal antibody directed against PD-L1/B7-H1/CD274, is also a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug. Preliminary phase I trial data demonstrate an ORR of 16 % among 58 evaluable pretreated advanced NSCLC patients (Adrian G Sacher et al. 2015).
Avelumab —— made by Merck KGaA, is a PD-L1/B7-H1/CD274 immune checkpoint inhibitors antibody that is being tested in a phase III trial versus chemotherapy in patients with NSCLC that has progressed after chemotherapy (NCT02395172).

Bladder cancer MPDL3280A —— an anti-PD-L1/B7-H1/CD274 monoclonal antibody, has been tested in a phase I trial of patients with metastatic urothelial bladder cancer (NCT02108652). Currently, this PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug is not FDA-approved for the treatment of bladder cancer.
Brain cancer MEDI4736—— a phase II trial testing MEDI4736 (durvalumab), an PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug, in patients with glioblastoma (NCT02336165).
Breast cancer MEDI4736, a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug made by MedImmune/AstraZeneca, is being tested in a a phase I trial for patients with solid tumors, including breast cancer (NCT01693562)
MPDL3280A a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug being developed by Roche/Genentech, is being tested in numerous cancers in a phase I trial (NCT01375842).
Cervical cancer MEDI4736—— a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug, is being tested in combination with tremelimumab, an anti-CTLA-4 antibody, in a phase I trial for patients with six kinds of cancer, including cervical cancer (NCT01975831).
Esophageal cancer Avelumab —— A phase I study of MSB0010718C, a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug being developed by EMD Serono, was conducted in solid tumors, including esophageal cancer (NCT01772004).
Kidney Cancer MPDL3280A—— a phase II study of MPDL3280A, a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug being developed by Roche/Genentech, as monotherapy or in combination with Avastin (bevacizumab) versus sunitinib in patients with untreated advanced renal cell carcinoma (NCT01984242).
MEDI4736 —— a phase I trial of tremelimumab (CTLA-4 immune checkpoint inhibitor) and MEDI4736 (PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug), made by MedImmune, for patients with advanced solid tumors, including renal carcinoma (NCT01975831).
Liver cancer MPDL3280A, a PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug developed by Roche/Genentech, is being tested in numerous cancers in a phase I trial in patients without hepatitis B or C (NCT01375842).
Lymphoma MPDL3280A —— A phase Ib study of the PD-L1/B7-H1/CD274 immune checkpoint inhibitors drug, MPDL3280A in combination with obinutuzumab (an anti-CD20 antibody) is conducted in patients with relapsed or refractory follicular lymphoma or diffuse large B cell lymphoma (NCT02220842)

PD-L1/B7-H1/CD274 Immune Checkpoint Inhibitors: Relatives

PD1/PDCD1/CD279 immune checkpoint inhibitors
CTLA-4/CD152 immune checkpoint inhibitors
B7-H3/CD276 immune checkpoint inhibitors
Indoleamine 2,3‑dioxygenase/IDO immune checkpoint inhibitors
KIR immune checkpoint inhibitors
LAG3 / CD223 immune checkpoint inhibitors
Immune Checkpoint
What is immune checkpoint?
Immune checkpoint targets
Immune checkpoint blockade: blocking antibodies
Immune checkpoint detection: antibodies
Immune checkpoint proteins
Immune checkpoint inhibitors
Immune checkpoint therapy
Immune checkpoint pathways
PD1 / PDCD1 / CD279 immune checkpoint
VISTA / B7-H5 / GI24 immune checkpoint